Treatment of rheumatoid tenosynovitis with cytokine inhibitors

Lancet. 2002 Nov 16;360(9345):1565-6. doi: 10.1016/S0140-6736(02)11529-7.

Abstract

Hand function depends on tendon integrity, but in rheumatoid arthritis tenosynovitis can result in tendon adhesions and rupture. Cytokine inhibitors have proved effective in rheumatoid joint disease; however, their effect on the tenosynovium is not well understood. We investigated the ability of inhibitors of tumour necrosis factor alpha and interleukin 1 to reduce production of collagenolytic matrix metalloproteinases 1 and 13 in tenosynovial tissue obtained from patients with rheumatoid arthritis. Our data show that cytokine blockade can reduce collagenase concentrations in tenosynovial tissue, suggesting cytokine inhibitors could be effective in reduction of tendon damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Collagenases / biosynthesis
  • Collagenases / drug effects*
  • Humans
  • Matrix Metalloproteinase 1 / biosynthesis
  • Matrix Metalloproteinase 1 / drug effects*
  • Matrix Metalloproteinase 13
  • Receptors, Interleukin-1 / antagonists & inhibitors*
  • Tenosynovitis / drug therapy*
  • Tenosynovitis / enzymology*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Receptors, Interleukin-1
  • Tumor Necrosis Factor-alpha
  • Collagenases
  • MMP13 protein, human
  • Matrix Metalloproteinase 13
  • Matrix Metalloproteinase 1